Glucocorticoid

ApprovedSmall molecule

Glucocorticoid is one of 365 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.

Indications

Total Trials

Active Trials

364

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Polymyalgia RheumaticaActive, not recruiting

Muscular DystrophyActive, not recruiting

Pulmonary HypertensionActive, not recruiting

Pulmonary SarcoidosisActive, not recruiting

Granulomatosis With PolyangiitisActive, not recruiting

Chronic RhinosinusitisActive, not recruiting

Septic ShockActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

Prostate CancerActive, not recruiting

Systemic Lupus ErythematosusApproved

Active, not recruiting

Polymyalgia RheumaticaPhase 2

Active, not recruiting

Muscular DystrophyPhase 3

Active, not recruiting

Pulmonary HypertensionPreclinical

Active, not recruiting

Pulmonary SarcoidosisPreclinical

Active, not recruiting

Granulomatosis With PolyangiitisPhase 2

Active, not recruiting

Chronic RhinosinusitisPreclinical

Active, not recruiting

Septic ShockPreclinical

Active, not recruiting

Interstitial Lung DiseasePhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Glucocorticoid

AbbVie

Approved

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Singulair

AstraZeneca

Preclinical

1 7

Stivarga

Bayer

Preclinical

1 8

Aimovig

Amgen

Preclinical

1 9

Aldactone

Pfizer

Preclinical

1 10

Nexavar

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalRecruiting

Systemic Lupus Erythematosus

NCT05916781

Q4 2026

N/ARecruiting

Efficacy and Safety

NCT06654596

Q2 2027

Phase 2Recruiting

Glomerulonephritis Rapidly Progressive

NCT06047171

Q3 2028

Phase 1/2Not yet recruiting

Diffuse Large B-Cell Lymphoma

NCT07159906

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05606107·230 enrolled

Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

Not yet recruiting·SSunnybrook Health Sciences Centre·Phase 4·NCT07245732·220 enrolled

Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients

Completed·UUniversity Hospital, Toulouse·Phase 4·NCT02997605·102 enrolled

Prostate Cancer2 trials

An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Completed·CCougar Biotechnology, Inc.·Phase 2·NCT00474383·47 enrolled

An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01664728·54 enrolled

Glucocorticoid2 trials

Sinomenine Versus Glucocorticoid for Knee OA

Unknown status·SShanghai 6th People's Hospital·Phase 3·NCT05764304·328 enrolled

Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs)

Unknown status·PPremier Specialists, Australia··NCT05525065·138 enrolled

Elderly1 trial

Rituximab in Pretreated Elderly or Unfit B-CLL Patients

Completed·—·Phase 2·NCT01576588·25 enrolled

Muscular Dystrophy1 trial

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

Active, not recruiting· Sarepta Therapeutics logo

Sarepta Therapeutics·Phase 3·NCT06246513·17 enrolled

17 more indications

Pediatric1 trial

Stratified Therapy on Pediatric AAGN

Unknown status·WWang Mo·Phase 4·NCT05969522·200 enrolled

Polymyalgia Rheumatica1 trial

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154

Terminated· AbbVie logo

AbbVie·Phase 2·NCT04972968·181 enrolled

Systemic Lupus Erythematosus1 trial

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus

Recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT05916781·220 enrolled

Interstitial Lung Disease1 trial

MSC for Treatment of Interstitial Lung Disease After Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 1/2·NCT02543073·60 enrolled

Septic Shock1 trial

Effects of Glucocorticoid Combined With Vitamin C and Vitamin B1 on Microcirculation in Severe Septic Shock

Completed·SSoutheast University, China·N/A·NCT03821714·22 enrolled

COVID-191 trial

The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19

Unknown status·HHuashan Hospital·N/A·NCT05855395·5,815 enrolled

Function1 trial

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

Completed·WWashington University School of Medicine·N/A·NCT00805207·61 enrolled

Botulinum Toxin1 trial

Clinical Effects of Incobotulinum Toxin vs Corticosteroid in Plantar Fascitis

Active, not recruiting·IInstituto Mexicano del Seguro Social·Phase 1·NCT06788158·20 enrolled

Granulomatosis with Polyangiitis1 trial

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

Completed·IInflaRx GmbH·Phase 2·NCT03895801·57 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 1/2·NCT07159906·62 enrolled

Pulmonary Sarcoidosis1 trial

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT03324503·8 enrolled

Chronic Rhinosinusitis1 trial

Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis After Endoscopic Sinus Surgery

Completed·ZZheng Liu·N/A·NCT02182492·187 enrolled

Pulmonary Hypertension1 trial

Glucocorticoids and Pulmonary Hypertension

Unknown status·WWashington University School of Medicine··NCT04499196·40 enrolled

Heart Failure1 trial

The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure

Completed·HHebei Medical University·Phase 2/3·NCT00953303·102 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Telitacicept in IgAN

Recruiting·RRuijin Hospital·N/A·NCT06654596·118 enrolled

Glomerulonephritis Rapidly Progressive1 trial

A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive Glomerulonephritis

Recruiting·AAlentis Therapeutics AG·Phase 2·NCT06047171·80 enrolled

Immunoglobulin G4 Related Disease1 trial

A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07190196·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Glucocorticoid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucocorticoid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucocorticoid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

Glucocorticoid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q3 2028

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Prostate Cancer2 trials

Glucocorticoid2 trials

Elderly1 trial

Muscular Dystrophy1 trial

Pediatric1 trial

Polymyalgia Rheumatica1 trial

Systemic Lupus Erythematosus1 trial

Interstitial Lung Disease1 trial

Septic Shock1 trial

COVID-191 trial

Function1 trial

Botulinum Toxin1 trial

Granulomatosis with Polyangiitis1 trial

Diffuse Large B-Cell Lymphoma1 trial

Pulmonary Sarcoidosis1 trial

Chronic Rhinosinusitis1 trial

Pulmonary Hypertension1 trial

Heart Failure1 trial

Efficacy and Safety1 trial

Glomerulonephritis Rapidly Progressive1 trial

Immunoglobulin G4 Related Disease1 trial

References

Drug Info

Quick Facts

Related News